FDA Determines Regulatory Review Period for SOMATULINE DEPOT Patent Extension

Summary

The Food and Drug Administration (FDA) has officially announced the regulatory review period for the patent extension of SOMATULINE DEPOT, a human drug product, following a submission to the Director of Patents and Trademarks at the Department of Commerce.